Log in

NYSE:PRGOPerrigo Stock Price, Forecast & News

$50.45
-0.01 (-0.02 %)
(As of 08/7/2020 04:00 PM ET)
Add
Compare
Today's Range
$49.74
Now: $50.45
$50.75
50-Day Range
$50.46
MA: $55.28
$58.54
52-Week Range
$40.01
Now: $50.45
$63.86
Volume937,293 shs
Average Volume906,219 shs
Market Capitalization$6.89 billion
P/E Ratio28.99
Dividend Yield1.78%
Beta1.16
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments. It offers OTC products in cough, cold, allergy, sinus, analgesic, gastrointestinal, smoking cessation, infant formula and food, animal health, diagnostic, lifestyle, personal care and derma-therapeutics, natural health and vitamins, minerals and dietary supplements, feminine hygiene, diabetes care, scar management, and anti-parasite categories under the Good Sense, Sergeant's, Sentry, Zephrex D, PetArmor, and ScarAway brand names. The company also develops, manufactures, and markets a portfolio of generic prescription drugs, such as creams, ointments, lotions, gels, shampoos, foams, suppositories, sprays, liquids, suspensions, solutions, powders, controlled substances, injectable, hormones, oral solid dosage forms, and oral liquid formulations. In addition, it offers contract manufacturing services. The company offers its products through retail drug, supermarket, and mass merchandise chains; hospitals; pharmacies; wholesalers; drug and grocery stores; and para pharmacies, as well as through a network of pharmacy sales force. It operates in Europe, Australia, Israel, Mexico, the United States, Canada, and China. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Read More
Perrigo logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.78 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP71429010
Phone353-1709-4000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.84 billion
Cash Flow$6.92 per share
Book Value$43.31 per share

Profitability

Net Income$146.10 million

Miscellaneous

Employees11,200
Market Cap$6.89 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$50.45
-0.01 (-0.02 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRGO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Perrigo (NYSE:PRGO) Frequently Asked Questions

How has Perrigo's stock been impacted by COVID-19 (Coronavirus)?

Perrigo's stock was trading at $46.04 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRGO shares have increased by 9.6% and is now trading at $50.45.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Perrigo?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Perrigo
.

When is Perrigo's next earnings date?

Perrigo is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Perrigo
.

How were Perrigo's earnings last quarter?

Perrigo Company PLC (NYSE:PRGO) released its quarterly earnings data on Wednesday, August, 5th. The company reported $1.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.87 by $0.16. The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.23 billion. Perrigo had a return on equity of 10.05% and a net margin of 4.73%. Perrigo's revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.86 EPS.
View Perrigo's earnings history
.

How often does Perrigo pay dividends? What is the dividend yield for Perrigo?

Perrigo declared a quarterly dividend on Wednesday, July 29th. Shareholders of record on Friday, August 28th will be given a dividend of $0.225 per share on Tuesday, September 15th. This represents a $0.90 dividend on an annualized basis and a dividend yield of 1.78%. The ex-dividend date is Thursday, August 27th.
View Perrigo's dividend history
.

What guidance has Perrigo issued on next quarter's earnings?

Perrigo issued an update on its FY20 earnings guidance on Wednesday, August, 5th. The company provided EPS guidance of $3.95-4.15 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.07. The company issued revenue guidance of $5.13-5.18 billion, compared to the consensus revenue estimate of $5.02 billion.

What price target have analysts set for PRGO?

8 brokers have issued 12-month target prices for Perrigo's stock. Their forecasts range from $53.00 to $70.00. On average, they anticipate Perrigo's stock price to reach $58.43 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts' price targets for Perrigo
.

Has Perrigo been receiving favorable news coverage?

Press coverage about PRGO stock has trended extremely negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Perrigo earned a news impact score of -4.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Perrigo
.

Who are some of Perrigo's key competitors?

What other stocks do shareholders of Perrigo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Netflix (NFLX), Allergan (AGN), Johnson & Johnson (JNJ), Celgene (CELG), Intel (INTC) and QUALCOMM (QCOM).

Who are Perrigo's key executives?

Perrigo's management team includes the following people:
  • Mr. Murray S. Kessler, CEO, Pres & Director (Age 59)
  • Mr. Todd W. Kingma, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Mr. Jeffrey R. Needham, Exec. VP & Pres of Consumer Healthcare Americas (Age 63)
  • Mr. Svend Andersen, Exec. VP & Pres of Consumer Healthcare International (Age 57)
  • Mr. Ronald L. Winowiecki, Advisory (Age 53)

What is Perrigo's stock symbol?

Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."

Who are Perrigo's major shareholders?

Perrigo's stock is owned by a number of institutional and retail investors. Top institutional investors include Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management (1.51%), Harel Insurance Investments & Financial Services Ltd. (0.50%), Swiss National Bank (0.39%), Manning & Napier Group LLC (0.29%), UBS Group AG (0.24%) and Victory Capital Management Inc. (0.16%). Company insiders that own Perrigo stock include Geoffrey M Parker, Grainne Quinn, Murray S Kessler, Ronald Craig Janish, Ronald Winowiecki, Svend Andersen, Theodore R Samuels II and Todd W Kingma.
View institutional ownership trends for Perrigo
.

Which institutional investors are selling Perrigo stock?

PRGO stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Mivtachim The Workers Social Insurance Fund Ltd. Under Special Management, Arizona State Retirement System, Andra AP fonden, Vident Investment Advisory LLC, Vident Investment Advisory LLC, Edmond DE Rothschild Holding S.A., and LSV Asset Management. Company insiders that have sold Perrigo company stock in the last year include Grainne Quinn, Ronald Craig Janish, Ronald Winowiecki, and Todd W Kingma.
View insider buying and selling activity for Perrigo
.

Which institutional investors are buying Perrigo stock?

PRGO stock was acquired by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., UBS Group AG, Assenagon Asset Management S.A., Duality Advisers LP, Franklin Street Advisors Inc. NC, SG Americas Securities LLC, Robeco Institutional Asset Management B.V., and Coho Partners Ltd.. Company insiders that have bought Perrigo stock in the last two years include Geoffrey M Parker, Murray S Kessler, Svend Andersen, Theodore R Samuels II, and Todd W Kingma.
View insider buying and selling activity for Perrigo
.

How do I buy shares of Perrigo?

Shares of PRGO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Perrigo's stock price today?

One share of PRGO stock can currently be purchased for approximately $50.45.

How big of a company is Perrigo?

Perrigo has a market capitalization of $6.89 billion and generates $4.84 billion in revenue each year. The company earns $146.10 million in net income (profit) each year or $4.03 on an earnings per share basis. Perrigo employs 11,200 workers across the globe.

What is Perrigo's official website?

The official website for Perrigo is www.perrigo.com.

How can I contact Perrigo?

Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The company can be reached via phone at 353-1709-4000 or via email at [email protected]

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.